Most articles offering a “GLP-1 medication names list” present the same flat table of brand names and generic molecules. Readers finish them knowing what exists but still unsure which name, if any, applies to them.
A names list answers “what exists.” It does not answer “what applies to me.” The second question carries real clinical weight, and a table cannot answer it.
Three sources of confusion explain the gap:
- One molecule can carry multiple brand names, each tied to a different approved use.
- A widely used medication is not technically a pure GLP-1.
- Compounded medications appear on no official approved list at all.
The takeaway is simple: a names list is a starting point for research, not a menu for self-selection. Matching a molecule to an indication and a health history is a decision made with a provider.
Why One Molecule Can Carry Multiple Brand Names
Pharmaceutical companies often bring the same active molecule to market under separate brand names when it is studied and FDA-approved for different indications. The most common pattern is a molecule approved under one brand for type 2 diabetes and under a related brand for chronic weight management.
The two versions can differ in several ways:
- Dosing schedules, which vary with the condition being treated.
- Formulation and strength, which may differ between products.
- Delivery method, meaning injection or tablet.
An oral tablet within this class also exists and is approved specifically for type 2 diabetes. That adds another axis of difference, injectable versus oral, that stays hidden inside a single row of a names list.
For the reader, this means a name on a list reveals almost nothing about which indication it was approved for or whether it fits a particular health profile.
The Dual-Agonist Problem: Why Not Every Medication on a GLP-1 List Is a Pure GLP-1
Tirzepatide is often grouped with GLP-1 medications in consumer content. Mechanistically, it is a dual agonist: it activates both the GLP-1 receptor and the GIP receptor, not the GLP-1 receptor alone.
The distinction is clinical, not just a matter of labels. A dual-receptor mechanism is a different pharmacological tool. Treating it as interchangeable with single-receptor GLP-1 agonists oversimplifies how these medications act in the body.
Tirzepatide follows the same “one molecule, two names” pattern described above. It is marketed under one brand for type 2 diabetes and another for chronic weight management.
The broader landscape includes several kinds of tools: brand-name GLP-1s like Zepbound, compounded GLP-1s, and Red Mountain’s own legacy RM3® program. Each occupies a different place, and none can be understood from a name alone.
The category is also still changing. Investigational triple agonists, which activate GLP-1, GIP, and glucagon receptors, remain in Phase 3 trials. Calling everything in this space “a GLP-1” is shorthand, and it hides mechanistic differences a provider must account for.
One Class, Six Indications: Why These Medications Aren’t Interchangeable
The broader class now spans six FDA-approved indication categories across ten marketed products:
- Type 2 diabetes
- Obesity and overweight
- Established cardiovascular disease
- Chronic kidney disease
- MASH (a progressive liver condition)
- Obstructive sleep apnea
These indications are spread unevenly across individual products. Approvals belong to specific products, and one product’s approval does not automatically extend to another.
Sleep apnea shows the pattern clearly. Moderate-to-severe obstructive sleep apnea approval in adults with obesity belongs to specific weight-management injectables. In at least one case, the diabetes-branded version of the same molecule does not carry that approval.
MASH follows the same logic. An accelerated approval granted in 2025 for one specific injectable formulation does not extend to other dosage forms or other products in the family.
The same applies across the class. A product approved to reduce cardiovascular risk in people with type 2 diabetes is not automatically approved for weight loss, and the reverse is also true. Approval is indication-specific, not molecule-wide.
One more detail: no medication in this class currently carries an FDA-approved indication for prediabetes, although off-label use is common in clinical practice. A flat names list leaves this out.
The Newest Entrant: An Oral, Non-Peptide Option Changes the List Again
On April 1, 2026, the FDA approved orforglipron, the first oral GLP-1 receptor agonist that can be taken without fasting or food-and-water timing restrictions.
The difference is structural, not just a new way of delivering the drug. Most medications in this class are peptides, which the gut absorbs poorly, so they usually require injection. Orforglipron is a non-peptide small molecule.
Its approved indication is weight management in adults with obesity, or with overweight plus at least one weight-related comorbidity.
This supports the article’s broader point. Any names list compiled before April 2026 is already out of date, and the category keeps adding entries faster than static articles can update. A new name still requires the same clinical evaluation as an established one.
Why Compounded GLP-1 Medications Don’t Appear on Any Approved Names List
Official drug lists catalog FDA-approved products. A compounded GLP-1 medication is prepared by a licensed pharmacy for an individual patient rather than catalogued as a listed product. Approved-product lists therefore leave it out by design.
The regulatory context has shifted quickly:
- December 2024: Tirzepatide came off the FDA’s drug shortage list.
- February 2025: Semaglutide followed, which changed the conditions under which pharmacies may compound.
- January 2026: An industry executive estimated that as many as 1.5 million Americans were using compounded medications in this class.
- February 2026: The FDA Commissioner announced the agency’s intent to restrict GLP-1 active ingredients being mass-marketed by compounding pharmacies and telehealth companies.
- April 30, 2026: The FDA proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the list that permits large-scale (503B) compounding.
A narrower path remains. Under Section 503A, a state-licensed pharmacy may compound for an individual patient, but only under specific conditions, including a prescriber’s determination that a clinically meaningful difference is needed for that patient.
A table of approved brand names cannot capture something that is not an approved brand-name product. Questions about a compounded GLP-1 medication therefore call for a direct clinical conversation.
Why Competitor Lists Can’t Agree on a Basic Number
Public “GLP-1 list” articles cite anywhere from roughly 7 to 14 drugs, even though they describe the same category. The disagreement usually comes from three choices:
- Whether tirzepatide counts as a “true” GLP-1.
- Whether a discontinued medication, no longer marketed, is included.
- Whether the new oral entrant is included.
Most tables also fail to separate “approved for diabetes” from “approved for weight management” from “off-label use.” They merge clinically important distinctions into a single column.
The disagreement is more than a small inconsistency. It shows what happens when a clinical classification is treated as a consumer checklist. A precise, dated, indication-aware breakdown is more useful than a longer list, because completeness is not the same as clarity.
The Real Takeaway: A List Is a Starting Point, Not a Menu
A names list helps readers recognize terminology. It cannot determine which medication is appropriate for a given person. That depends on factors no static list can capture:
- Current health conditions and prior diagnoses
- Other medications
- Specific goals, whether metabolic, cardiovascular, weight-related, or sleep-related
- How the body has responded to past treatment
Medication is one tool within a broader plan. The same molecule can sit inside very different treatment plans depending on the person.
This is where Red Mountain’s clinical model fits. The practice draws on more than 30 years of real-world patient outcomes and provides in-person oversight at brick-and-mortar clinics. That structure helps people understand where they fit in this landscape. Its programs are also designed to support patients alongside any medication, with attention to minimizing side effects, preserving muscle mass, and maintaining nutrient balance.
Whether someone is exploring a brand-name option, discussing a compounded GLP-1 medication, or considering a proprietary program, the right next step is a clinical conversation.
Conclusion: Read the List, Then Talk to a Provider
Confusion about GLP-1 medication names is not the reader’s failure. It is a predictable result of compressing six indications, multiple mechanisms, and a shifting regulatory landscape into one flat table.
Three structural reasons keep a names list from standing on its own:
- Shared molecules carry brand names tied to specific indications.
- A dual agonist is commonly miscategorized as a pure GLP-1.
- A compounded category exists outside any approved-names framework.
Research starts with a list. Decisions happen in a provider conversation, because matching molecule, indication, and personal history is clinical work.
Next Step: Turning a List Into a Plan
If this breakdown raised more questions than it answered, that is expected for a category this complex and fast-moving.
Red Mountain’s consult process is built for this kind of sorting. Providers review health history, current labs, and personal goals before any medication or program is discussed. For anyone who recognizes their own questions here, a consult is usually the next step: a place to have these distinctions explained in the context of their own health, without committing to anything.
Red Mountain may prescribe a compounded version of a GLP-1. Compounded GLP-1s contain semaglutide or tirzepatide. Compounded GLP-1s have not been approved by the FDA or reviewed by the FDA for safety, effectiveness, or quality. Compounded GLP-1s have not been demonstrated to the FDA to be safe or effective for weight loss. Compounded GLP-1s manufacturing processes have not been reviewed by the FDA. FDA-approved products containing semaglutide and tirzepatide are available. Ask your provider for more information.
